Last reviewed · How we verify
EXG110 Injection
At a glance
| Generic name | EXG110 Injection |
|---|---|
| Sponsor | Guangzhou Jiayin Biotech Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease (NA)
- The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EXG110 Injection CI brief — competitive landscape report
- EXG110 Injection updates RSS · CI watch RSS
- Guangzhou Jiayin Biotech Ltd portfolio CI